DNA Biomedical Solutions Ltd. (TASE: DNA) subsidiary Entera Bio Ltd. has successfully completed a preclinical trial of its oral treatment for osteoporosis, the company's first drug. The trial included ten tests on pigs to measure the absorption of the drug's active pharmaceutical ingredient (API) by the bloodstream (bioavailability).
The tests found a bioavailability level of over 7%, which was higher than expected by Entera before the trial.
Entera is now preparing for a Phase I human clinical trial to test the preliminary safety and efficacy of the drug.
DNA Biomedical estimates the US market for osteoporosis treatments at $10 billion a year.
DNA and Oramed Pharmaceuticals Inc. (Bulletin Board:ORMP); DAX:OJU) set up Entera Bio in June 2010, owning it in equal shares. DNA subsequently bought most of Oramed's holding to reach a 97% stake in the venture.
DNA's share price rose 2.5% by midday to NIS 0.29, giving a market cap of NIS 38 million.
Published by Globes [online], Israel business news - www.globes-online.com - on March 6, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011